

## PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1  
Stylesheet Version v1.2

EPAS ID: PAT3083062

|   |  |
|---|--|
| <b>SUBMISSION TYPE:</b>   | NEW ASSIGNMENT   |
| <b>NATURE OF CONVEYANCE:</b>  | EXECUTIVE ORDER 9424, CONFIRMATORY LICENSE   |
| <b>CONVEYING PARTY DATA</b>   |  |
| <b>Name</b>   | <b>Execution Date</b>  |
| SLOAN-KETTERING INS CAN RES   | 02/21/2014   |
| <b>RECEIVING PARTY DATA</b>   |  |
| <b>Name:</b>  | National Institutes of Health (NIH), U.S. Dept. of Health and Human Services (DHHS), U.S. Government |
| <b>Street Address:</b>  | NIH Division of Extramural Inventions and Technology Resources (DEITR)                               |
| <b>Internal Address:</b>  | 6705 Rockledge Drive, Suite 310, MSC 7980  |
| <b>City:</b>  | Bethesda   |
| <b>State/Country:</b>   | MARYLAND   |
| <b>Postal Code:</b>   | 20892-7980   |
| <b>PROPERTY NUMBERS Total: 1</b>  |  |
| <b>Property Type</b>  | <b>Number</b>  |
| Application Number:   | 13974405   |
| <b>CORRESPONDENCE DATA</b>  |  |
| <b>Fax Number:</b>  | (301)480-0272  |
| <i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i> |  |
| <b>Email:</b>   | edison@nih.gov   |
| <b>Correspondent Name:</b>  | DIRECTOR, DEITR  |
| <b>Address Line 1:</b>  | NIH, 6705 ROCKLEDGE DRIVE, SUITE 310   |
| <b>Address Line 2:</b>  | MSC 7980   |
| <b>Address Line 4:</b>  | BETHESDA, MARYLAND 20892-7980  |
| <b>NAME OF SUBMITTER:</b>   | DIRECTOR, DEITR, NIH   |
| <b>SIGNATURE:</b>   | /Director, DEITR, NIH/   |
| <b>DATE SIGNED:</b>   | 10/28/2014   |
| <b>Total Attachments: 1</b>   |  |
| source=13974405,LAB,10-28-2014#page1.tif  |  |

SIL1298-09

# License to the United States Government

Sign and submit the executed document to the appropriate funding agency (e.g. upload in iEdison).

Invention Title: Cytotoxic T cells induce ceramide-enriched platform formation to signal apoptosis

Inventor(s): Wadih Arap, Richard N Kolesnick, Renata Pasqualini, Jimmy A Rotolo

U.S. Filing/Issue Date: 08/23/2013

Patent or Application Serial No.: 13/1974,405

Grant/Contract Number(s): CA095704

Foreign Applications filed/intended in (countries): \_\_\_\_\_

The invention identified above is a Subject Invention under 35 U.S.C. 200, et seq., and the Standard Patent Rights clause at 37 CFR 401.14, FAR 52.227-11 or FAR 52.227-12 (if applicable) which are included among the terms of the above identified grant or contract award from the United State Government. This document is confirmatory of:

1. The nonexclusive, nontransferable, irrevocable, paid-up license to practice or have practiced for or on behalf of the United States the invention described in any patent application and in any and all divisions, continuations, and continuations in part, and in any and all patents and re-issues granted thereon throughout the world; and
2. All other rights acquired by the Government by reason of the above identified grant/contract award and the laws and regulations that are applicable to the award.

The Government is hereby granted an irrevocable power to inspect and make copies of the above-identified patent application.

Signed this 21<sup>st</sup> day of February, 2014.

By Gregory Reskin, M.D.  
Vice President, Technology Development  
(Institutional Business Official)  
Memorial Sloan Kettering Cancer Center

[Signature]  
(Signature)

Title \_\_\_\_\_

For SLOAN-KETTERING INST CAN RES  
(Grantee/Contractor Organization)

At Office of Technology Development 1275 York Avenue New York, NY 10065 UNITED STATES  
(Business Address)